Prosecution Insights
Last updated: November 12, 2026
Application No. 18/689,751

INDUCIBLE PROMOTER, VECTOR AND HOST CELL BASED THEREON

Non-Final OA §103§112
Filed
Mar 06, 2024
Priority
Sep 07, 2021 — RU 2021126254 +1 more
Examiner
KASAYAN, KATRIEL BARCELLANO
Art Unit
1634
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Joint Stock Company «Biocad»
OA Round
1 (Non-Final)
25%
Grant Probability
At Risk
1-2
OA Rounds
25%
With Interview

Examiner Intelligence

Grants only 25% of cases
25%
Career Allowance Rate
1 granted / 4 resolved
-35.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
35 currently pending
Career history
38
Total Applications
across all art units

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This action is in response to papers filed on 7/28/2026. A response to the restriction requirement filed on July 28, 2026, is acknowledged. Claims 1-9 are currently pending as per claims filed March 4, 2026. Claims 10-20 have been withdrawn from consideration by Applicants’ amendment filed on 3/4/2026. No claims were canceled or newly added. Applicants’ election without traverse of Group I, directed to an inducible promoter comprising STAT3, STAT5, AP-1 and a minimal promoter, e.g., claims 1-9 is acknowledged. Claims 10-20 have been withdrawn from further consideration by Applicants, pursuant to 37 CFR 1.142(b), as being drawn to a non-elected invention, there being no allowable generic or linking claim. The restriction requirement is deemed proper, maintained and made FINAL. Therefore, claims 1-9 are under examination to which the following grounds of rejection are applicable. Priority The present application is a 35 U.S.C. 371 national stage filing of International Application No. PCT/RU2022/050279, filed 09/06/2022, which claims priority to Russian Application No. 2021126254, filed 09/07/2021. The certified untranslated copy of the RUSSIAN FEDERATION 2021126254 09/07/2021 publication was filed on 3/6/2024. Should applicant desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)-(d) prior to declaration of an interference, a certified English translation of the foreign application must be submitted in reply to this action. 37 CFR 41.154(b) and 41.202(e). Failure to provide a certified translation may result in no benefit being accorded for the non-English application. Therefore, the earliest possible priority for the instant application is September 7, 2021. Specification The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-9 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for the specific arrangement of binding sites of transcription factors, specifically in the order of STAT3, STAT5 and AP-1, including the combined sequence represented by SEQ ID NO: 13, does not reasonably provide enablement for the claimed genus of inducible promoter encompassing alternative STAT3, STAT5, and AP-1 binding-unit sequences, combinations, and arrangements in conjunction with a minimal promoter. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims. The criteria for enablement set out In re Wands, MPEP 2162.01(a), considers the following factors: Breadth of the Claims The claims are broadly directed to a broad genus of inducible promoters comprising STAT3, STAT5, and AP-1 transcription factor binding units in conjunction with a minimal promoter. The claimed scope is not limited to the specific order of STAT3-STAT5-AP-1 disclosed in SEQ ID NO: 13 but rather encompasses alternative binding-unit sequences and combinations thereof. The claims encompass sequences selected from the group of SEQ ID Nos: 10-12, whereas SEQ ID NO: 13 represents the disclosed combination of STAT3, STAT5 and AP-1 binding sequences. Thus, the claims encompass promoter embodiments beyond the combined sequence and are only enabling for the combined sequence disclosed in SEQ ID NO: 13. State of Prior Art The prior art demonstrates that transcriptional activity of a promoter is heavily influenced by the order of the binding sites for transcription factors, their positioning and spacing, and interactions between transcription factors bound to such sites. Lerner et al. (Published: 2003. Genes Dev. 2003 Oct 15;17(20):2564-77. Cited in ISR filed March 6 2024) investigated the relationship between transcription-factor binding sites and transcriptional activity within the STAT3-dependent rat α2-macroglobulin promoter (pp. 2564, Abstract). Lerner reveals that increasing the spacing of the STAT3 and AP-1 sites by 5 bases suppressed transcription by roughly 60% (pp. 2567, left col, para 2). Therefore, Lerner establishes that promoter activity is dependent not merely upon the presence of transcription-factor binding sites, but also upon their particular spatial arrangement. Thus, it is evident that it is highly unpredictable how promoter elements will respond to even very minor sequences space changes. Smith et al. (Published: 2013. Nat Genet. 2013 Sep;45(9):1021-1028. ) evaluated over 5000 synthetic regulatory elements (SREs) comprising combinations and arrangements of various transcription-binding sites and assessed their regulatory activity in HepG2 cells (pp. 1021, Abstract and pp. 1022, col 1, para 2). Smith specifically assessed that of 211 sets of SREs, 87 (41%) had a favorable permutation that resulted in significantly stronger increase in expression than an unfavorable mutation (pp. 1026, col 1, para 1). Further, some favorable mutations produced, on average, 2.8-fold higher expression than in unfavorable ones, with some pairs having as high as 6.8-fold higher expression (pp. 1026, col 1, para 1). Therefore, the prior art establishes that relative position and order of transcription-factor binding sites (e.g., SREs) within a promoter, can significantly impact transcriptional activity. Accordingly, the arrangement of STAT3-STAT5-AP-1 does not necessarily establish that alternative orders or combinations encompassed by claims 1-9 would exhibit comparable inducible transcriptional activity. Amount of Direction Provided by the Inventor The Specification provides insufficient direction and guidance to enable a person of ordinary skill in the art to practice the full scope of the claimed invention, as the Specification only discloses a single permutation of the order of transcriptional binding sites (STAT3-STAT5-AP1) rather than the full scope of the claims. The Specification discloses STAT3, STAT5, and AP-1 binding sequences (para 0112-0117) and also a specific arrangement of the 3 binding sites, wherein they arranged from 5′ end to 3′ end one after the other in the following order: STAT3-STAT5-AP-1 (para 0117). The specification also discloses that the specific arrangement of STAT3-STAT5-AP-1 can be repeated from 1-40 or more times (para 0118). Although the Specification provides specific embodiments to reproduce the general architecture of the inducible promoter, the Specification is silent on the specific functional consequences that arise when altering the order of the binding sites, number of repeats, and general spacing of binding sites encompassed broadly by the claims. Presence or Absence of Working Examples The Specification only provides working examples demonstrating the construction and use of a single inducible promoter system comprising the nucleotide of SEQ ID NO:13. . Specifically, Example 1 describes the construction of a reporter plasmid vector encoding the firefly luciferase gene under the control a universal reporter construct comprising transcription factors STAT3, STAT5, AP-1 and a minimal promoter (para 0160). The Specification also discloses that the binding sites were structured as three repeats of the arrangement of the transcription factor binding sites (para 0161-0162). Subsequent Examples 2-11 employ the same reporter construct and describe its use in a reporter cell line (para 0181-0185), and reactivity to biological stimuli such as IL-10 (par a0172-0174). However, these examples appear to only be enabling for one specific arrangement of transcription binding sites (STAT3-STAT5-AP-1) of SEQ ID NO:13, and do not provide working examples for the full scope of the claims. The Specification does not provide working examples for more than three repeats of the same reporter construct of SEQ ID NO:13, or alternative arrangements of STAT3, STAT5 and AP-1, or different spacing between each transcription binding site. As such, while the working examples establish the operability of a single reporter construct of SEQ ID NO: 13 wherein the binding sites of the transcription factors STAT3, STAT5 and AP-1 are arranged from 5′ end to 3′ end one after the other in the following order: STAT3-STAT5-AP-1 contiguously, the Specification provides limited working examples from which a skilled artisan could practice the full scope of the claims. Further, SEQ ID NO: 13 consists of SEQ ID NO: 10, SEQ ID NO:11 and SEQ ID NO: 12 with SEQ ID NOs aligned contiguously in the order: SEQ ID NO: 10 – SEQ ID NO: 11 – SEQ ID NO: 12. Alignment of the three nucleotide sequences that establish SEQ ID NO: 13 is listed below. PNG media_image1.png 488 786 media_image1.png Greyscale Quantity of Experimentation Necessary A person with ordinary skill in the art would not reasonably expect that other combinations or arrangements of STAT3, STAT5 or AP-1 would result in the same transcription activity as disclosed within the working examples. Although the Specification provides specific evidence for binding sites within the order of STAT3-STAT5-AP-1 of SEQ ID NO: 13 arranged from the 5’ to 3’ order, and that this regulatory element is repeated 3 times, the Specification is silent on the practice of other embodiments or iterations of these three binding sites and whether they have the same transcriptional activity as the single working example. For instance, the Specification is silent on whether different SEQ ID NOs for STAT3 (e.g. SEQ ID Nos 1-3), STAT5 ((e.g. SEQ ID Nos 4-6) and AP-1 (e.g. SEQ ID Nos 7-9) all are compatible sequences to generate the reporter construct and hold the same characteristics as the singular working example. A skilled artisan would have to determine which sequences are most favorable when generating the reporter construct or which combinations of these 9 sequences can generate the inducible reporter construct displayed in the working examples. Conclusion In light of the unpredictability surrounding the claimed subject matter in the art and lack of adequate guidance in the Specification, one wishing to practice the presently claimed invention would be unable to do so without engaging in undue experimentation. It is especially noted that applicants provide no data, examples, figures, etc. demonstrating that other combinations of the three transcription factors (STAT3, STAT5, AP-1) could reasonably result in the generation of an inducible promoter with the same desired transcriptional activity disclosed in the working examples, and if this can be applied to the full scope of the claims. Furthermore, the disclosure appears to only provide enablement sites of the transcription factors STAT3, STAT5 and AP-1 are arranged from 5′ end to 3′ end one after the other in the following order: STAT3-STAT5-AP-1, which is encompassed by SEQ ID: 13. Moreover, this example does not reasonably provide enablement for the broader scope of not only claim 1, but also claim 6, which requires the selection from the group of nucleotides sequences comprising SEQ ID NOs 10-12. A skilled artisan would require an undue amount of experimentation to determine if only one sequence selected from the group could provide the same individual promoter functionality. In the absence of such information, a person of ordinary skill in the art would reasonably require an undue quantity of experimentation. Claim Rejections - 35 USC § 103 To the extent that the claims encompass an inducible promoter comprising binding sites of transcription factors STAT3, STATS and AP-1 and a minimal promoter arranged in any order or number , the following rejection applies. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1 is/are rejected under 35 U.S.C. 103 as being unpatentable over Chappell et al. (Published: 2000. "STAT proteins play a role in tumor necrosis factor alpha gene expression" Shock 14(3):p 400-403), in view of Bednorz et al. (Endocrinology, Volume 152, Issue 5, 1 May 2011, Pages 1935–1947). Regarding claim 1, Chappell teaches a luciferase reporter vector consisting of, inter alia, the binding sites for STAT3, STAT 5/6, activator protein-1 (AP-1), and tumor necrosis factor alpha (hereinafter, TNFalpha) (pp. 400, Abstract). Furthermore, Chappell teaches that the minimal promoter is the TNFalpha promoter (pp. 400, col 2, para 4). However, Chappell does not explicitly disclose a minimal promoter. Bednorz discloses a STAT5 reporter gene construct that comprises STAT5 binding site, and A minimal promoter (Figure 1). Moreover, Bednorz teaches that various genes influenced by the STAT5 binding site, therefore the reporter construct comprises a minimal promoter (CMVmin and TA minimal promoter) and a bare response element so the construct could be more applicable to different cell types (pp. 1944, col 2, para 2). PNG media_image2.png 408 506 media_image2.png Greyscale It would have been prima facie obvious for a person with ordinary skill in the art to combine the reporter vector comprising the binding sites of STAT3, STAT5/6, AP-1, and TNFalpha promoter taught by Chappell, to further comprise a minimal promoter, as taught by Bednorz, to ensure that the reporter construct could be more applicable to different cell types. There would have been reasonable expectations of success in combining these teachings as one of ordinary skill in the art would recognize to combine known elements in the art to give predictable results. *** Claim(s) 1 and 2 is/are rejected under 35 U.S.C. 103 as being unpatentable over Chappell et al. (Published: 2000. "STAT proteins play a role in tumor necrosis factor alpha gene expression" Shock 14(3):p 400-403), in view of Bednorz et al. (Endocrinology, Volume 152, Issue 5, 1 May 2011, Pages 1935–1947) as applied to claim 1, in further view of Lerner et al. (Published: 2003. Genes Dev. 2003 Oct 15;17(20):2564-77. Cited in ISR filed March 6 2024). With regard to claim 1, the combined teachings of Bednorz and Chappell render obvious the claimed product, as iterated above in the 103 rejection the content of which is incorporated in claim 1. However, Chappel fails to teach that the binding sites of transcription factor STAT3 is a nucleotide sequence selected from a group of nucleotide sequences consisting of SEQ ID NO: 3 Lerner teaches an α2-macroglobulin promoter, wherein the promoter comprises a STAT3 binding site with 100% sequence identity to SEQ ID NO: 3 (Figure 3 attached. Alignment attached below) PNG media_image3.png 814 978 media_image3.png Greyscale PNG media_image4.png 214 700 media_image4.png Greyscale It would have been obvious for a person with ordinary skill in the art to modify the luciferase reporter vector consisting of, inter alia, the binding sites for STAT3, STAT 5/6, activator protein-1 (AP-1), and tumor necrosis factor alpha (hereinafter, TNFalpha), with a STAT3 binding site consisting of SEQ ID NO: 3 taught by Lerner, as Lerner discloses that the sequence is known as a STAT3 binding site, thereby predictably providing a binding site to said transcription factor. There would have been reasonable expectations of success in combining these teachings as one of ordinary skill in the art would recognize to combine known elements in the art to give predictable results. Conclusion No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Katriel B Kasayan whose telephone number is (571)272-1402. The examiner can normally be reached 10-4p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maria G Leavitt can be reached at (571) 272-1085. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KATRIEL BARCELLANO KASAYAN/Examiner, Art Unit 1634 /MARIA G LEAVITT/Supervisory Patent Examiner, Art Unit 1634
Read full office action

Prosecution Timeline

Mar 06, 2024
Application Filed
Sep 09, 2026
Non-Final Rejection mailed — §103, §112 (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
25%
Grant Probability
25%
With Interview (+0.0%)
Low
PTA Risk
Based on 4 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month